The purpose of the Animal Genomics Shared Resource (AGS) is to create (and through cryopreservation, maintain) transgenic and knockout models for human diseases including cancer. The specific objectives are: 1) Provide consultation on transgene and targeting construct design;2) Introduce DNA into zygotes or embryonic stem cells;3) Create founder animals or chimeras that incorporate the desired, DNA addition or change;and 4) Cryopreserve mouse embryos for cost-effective, long-term storage of genetically engineered mice. The Transgenic mouse service was created in 1989. The ability to create knockout mice was added in 1997. Cryopreservation of mouse embryos has been performed since 2000. The creation of novel mouse strains, either by transgenesis or homologous recombination, allows many members of the Yale Cancer Center (YCC), to determine the normal function of genes and how perturbation of that function can result in aberrant development or diseases such as cancer. Investigators can use AGS to create direct analogs of mutations involved in human disease, thus providing models that can be studied in a way that human subjects cannot. The ability to create such induced mutants allows investigators to effectively use mouse genetics to dissect and analyze complicated developmental pathways, biochemical processes, and biomolecular interactions in a mammal to a level previously unattainable before such technology existed. This enables researchers to investigate biological processes at a far deeper level than in vitro methods such as biochemistry or cell culture will allow, and through the appearance of novel phenotypes resulting from induced mutations, discover new relationships between these processes and pathways. Cryopreservation of mouse strains allows investigators to more efficiently utilize their financial resources in research while maintaining valuable strains for future use. The YCC AGS produces 40-60 transgenic mouse strains/year, and creates 15-20 new targeted mutant mouse models/year. Animal Genomics Services has been a shared resource of the YCC since 1989. AGS moved into new space designed specifically for their use with the completion of The Anylan Center building in 2002. Twenty-eight YCC investigators used AGS in 2005 for a total of approx. 62% of all usage of the resource. All YCC usage during 2005 was from peer-reviewed scientists from 7 of 8 YCC Research Programs

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-31
Application #
7916696
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
31
Fiscal Year
2009
Total Cost
$182,741
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications